NLS Pharmaceutics Outlines Capital and Share Strategy

NLS Pharmaceutics (NLSP) has released an update.

NLS Pharmaceutics AG, a Swiss-based pharmaceutical company, has announced its purpose to engage in the research and development of various pharmaceutical and biotechnological products, alongside acquiring and managing intellectual property rights. The company’s share capital is CHF 937,600, divided into fully paid-in registered shares, with a capital band allowance for share capital increase set until September 2029. Moreover, the board of directors is empowered to issue new shares and manage preemptive rights, which can be allocated to third parties or used to meet listing requirements and enhance shareholder base.

For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.